CYTK catalysts
Catalysts and events linked to CYTK, newest first.
CYTK stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Cytokinetics Presents Positive Aficamten Phase 3 Data at ESC Congress 2026 2026-08-30 · Up | clinical trial pipeline de-risking | CYTK presented positive aficamten Phase 3 trial data at ESC Congress 2026. | Not recorded |
| Cytokinetics Presents Late-Breaking Aficamten Data at ESC Congress 2026 2026-08-30 · Up | clinical pipeline de-risking and market expansion | Late-breaking trial presentation at ESC Congress 2026 showing diastolic improvement in HCM. | Not recorded |
| Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026 2026-08-30 · Up | expanded addressable market and regulatory approval probability for aficamten | ACACIA-HCM and MAPLE-HCM late-breaking trial presentations at ESC Congress 2026. | Not recorded |
| Cytokinetics Presents Aficamten Cardiac Trial Data at ESC 2026 2026-08-30 · Up | clinical pipeline de-risking and addressable market expansion | Presented positive ACACIA-HCM and MAPLE-HCM trial results at ESC Congress 2026. | Not recorded |
| Cytokinetics Presents Aficamten HCM Data at ESC Congress 2026 2026-08-30 · Up | biotech commercial asset valuation expansion via positive Phase 3 ESC data | Aficamten ACACIA-HCM and MAPLE-HCM results presented in late-breaking session at ESC Congress. | Not recorded |
| Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026 2026-08-30 · Up | biotech pipeline derisking and expanded label market opportunity | ACACIA-HCM and MAPLE-HCM late-breaking trial readouts demonstrated cardiac structure improvements. | Not recorded |
| Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026 2026-08-30 · Up | commercial pipeline addressable market expansion | Aficamten demonstrated structural cardiac improvement in late-breaking clinical trials at ESC Congress. | Not recorded |
| Cytokinetics Presents Positive Aficamten Phase Data at ESC Congress 2026 2026-08-30 · Up | pipeline commercial valuation repricing via expanded HCM clinical label potential | ESC Congress late-breaking presentations showed structural and diastolic cardiac improvements for aficamten. | Not recorded |
Do these developments change your position?
Review CYTK alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-08-30Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026CYTK
- 2026-08-30Cytokinetics Presents Positive Aficamten Phase 3 Data at ESC Congress 2026CYTK
- 2026-08-30Cytokinetics Presents Aficamten Cardiac Trial Data at ESC 2026CYTK
- 2026-08-30Cytokinetics Presents Positive Aficamten Phase Data at ESC Congress 2026BMY CYTK
- 2026-08-30Cytokinetics Presents Aficamten Cardiac Trial Data at ESC 2026CYTK
- 2026-08-30Cytokinetics Presents Aficamten HCM Data at ESC Congress 2026CYTK
- 2026-08-30Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026CYTK
- 2026-08-30Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026BMY CYTK
- 2026-08-30Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026CYTK
- 2026-08-30Cytokinetics Presents Positive Aficamten Phase 3 Data at ESC Congress 2026CYTK
- 2026-08-30Cytokinetics Presents Late-Breaking Aficamten Data at ESC Congress 2026CYTK
- 2026-08-30Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026CYTK
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.